在风湿性关节炎管理的地平线上有什么新鲜事?
Karmtej S Cheema1, Andrew Bit Mansour2, Siba P Raychaudhuri3
1Department of Internal Medicine, University of California Davis Medical Center, Sacramento, CA, USA.
Best practice & research. Clinical rheumatology
|February 12, 2025
概括
早期类风湿性关节炎 (RA) 治疗对于预防长期残疾和心脏病等全身性问题至关重要. 本综述涵盖了新兴的基于免疫的疗法和未来的RA治疗药物.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 风湿性关节炎 (RA) 是一种慢性自身免疫性疾病,主要影响关节和肌肉骨系统.
- 早期干预对于预防长期残疾和诸如动脉样硬化和冠状动脉疾病等系统性并发症至关重要.
- 最近的进展包括新的生物和非生物抗风湿药物,转向"治疗到目标"战略.
研究的目的:
- 提供有关风湿性关节炎 (RA) 治疗当前发展的全面概述.
- 探索 RA 管理的潜在可用的治疗选择.
- 分析基于免疫的新型疗法和RA管道中的未来药物.
主要方法:
- 系统审查有关RA治疗的最新文献.
- 对目前和新兴的类风湿性关节炎药物治疗方法的分析.
- 评估针对RA的新型免疫疗法和管道中的药物.
主要成果:
- 新的生物和非生物抗风湿药物扩大了RA的治疗选择.
- 基于免疫的新型疗法显示出革命性抗 RA 治疗的巨大潜力.
- 目前有几种有前途的药物正在研发中,用于未来的RA治疗.
结论:
- 有效的RA早期治疗对于减轻患者长期发病率至关重要.
- 新兴的基于免疫的疗法代表了RA治疗的重大进步.
- 关节炎治疗的未来涉及到针对免疫系统的各种新治疗选择.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
99
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
99
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
114
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114
The JAK-STAT Signaling Pathway
8.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.6K
Autoimmune Disorders
379
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
379
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
374
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
374


